Deciphering the role of CHST14 in gastric cancer through in silico analysis

Abstract

Background: Gastric cancer’s heterogeneous nature and subtle symptoms necessitate the identification of reliable diagnostic and prognostic biomarkers.

Methods: CHST14 expression in gastric cancer was analyzed using TCGA and GTEx data. Differentially expressed genes were identified and visualized through ROC, survival, volcano plots, and nomograms. Functional analyses included GO and KEGG enrichment, drug sensitivity predictions from the GDSC database, and immune cell infiltration estimation using TIMER algorithms.

Results: CHST14 was overexpressed in gastric cancer tissues and correlated with poor overall survival and disease-specific survival, but showed no correlation with progression-free survival. Drug sensitivity analysis revealed CHST14’s positive association with chemotherapeutic agents such as SN-38, paclitaxel, and 5-fluorouracil, and negative correlation with others including BEZ235 and doxorubicin. Immune analysis showed CHST14 expression positively associated with infiltration of B cells, CD4+ T cells and CD8+ T cells, macrophages, neutrophils, and dendritic cells. Single-cell RNA sequencing data highlighted CHST14's role in cell-cell interactions, particularly between malignant cells and fibroblasts, and its involvement in tumor-stroma crosstalk. Enrichment analyses linked CHST14 to oncogenic pathways such as epithelial-mesenchymal transition, TNF-α signaling, and MAPK regulation.

Conclusion: CHST14 is a potential diagnostic and prognostic biomarker for gastric cancer, influencing drug metabolism and immune microenvironment interactions. These findings provide insights into CHST14’s mechanistic role in tumor progression and its potential as a therapeutic target. Further studies are required for clinical validation and mechanistic exploration.

Keywords

CHST14 / gastric cancer / diagnostic and prognostic marker / immune microenvironment.

References

[1] Smyth EC,Grabsch HI,Lordick F.Gastric cancer.Lancet2020;396:635-48

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Petryszyn P,Matysiak-Budnik T.Gastric cancer: where are we heading?.Dig Dis2020;38:280-5

[4] Sonkin D,Teicher BA.Cancer treatments: past, present, and future.Cancer Genet2024;286-287:18-24 PMCID:PMC11338712

[5] Zhang Z,Sun M.Research progress of immunotherapy for gastric cancer.Technol Cancer Res Treat2023;22:15330338221150555 PMCID:PMC10102952

[6] Gullo I,Oliveira C.Heterogeneity in gastric cancer: from pure morphology to molecular classifications.Pathobiology2018;85:50-63

[7] Malfait F,Vlummens P.Musculocontractural ehlers-danlos syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene.Hum Mutat2010;31:1233-9

[8] Miyake N,Mizumoto S.Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome.Hum Mutat2010;31:966-74

[9] Janecke AR,Müller T.Loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect, "dermatan sulfate-deficient adducted thumb-clubfoot syndrome".Hum Mutat2011;32:484-5

[10] Mendoza-Londono R,Kahr WH.Extracellular matrix and platelet function in patients with musculocontractural Ehlers-Danlos syndrome caused by mutations in the CHST14 gene.Am J Med Genet A2012;158A:1344-54

[11] Kosho T.CHST14/D4ST1 deficiency: New form of Ehlers-Danlos syndrome.Pediatr Int2016;58:88-99

[12] Mizumoto S,Hatamochi A.Defect in dermatan sulfate in urine of patients with Ehlers-Danlos syndrome caused by a CHST14/D4ST1 deficiency.Clin Biochem2017;50:670-7

[13] Sandal S,Panigrahi I.Novel mutation in the CHST14 gene causing musculocontractural type of Ehlers-Danlos syndrome.BMJ Case Rep2018;2018:bcr-2018 PMCID:PMC6157554

[14] Malfait F,Byers P.The 2017 international classification of the Ehlers-Danlos syndromes.Am J Med Genet C Semin Med Genet2017;175:8-26

[15] Kosho T,Watanabe T,Miyake N.Recent advances in the pathophysiology of musculocontractural Ehlers-Danlos syndrome.Genes2019;11:43 PMCID:PMC7017038

[16] Bian S,Bernreuther C.Dermatan sulfotransferase Chst14/D4st1, but not chondroitin sulfotransferase Chst11/C4st1, regulates proliferation and neurogenesis of neural progenitor cells.J Cell Sci2011;124:4051-63

[17] Zavros Y.The immune microenvironment in gastric adenocarcinoma.Nat Rev Gastroenterol Hepatol2022;19:451-67 PMCID:PMC9809534

[18] Uppal A,Chang SC.The immune microenvironment impacts survival in western patients with gastric adenocarcinoma.J Gastrointest Surg2020;24:28-38

[19] Wang B,Liu W.Targeting regulatory T cells in gastric cancer: pathogenesis, immunotherapy, and prognosis.Biomed Pharmacother2023;158:114180

[20] Jia L,Zhao Y.Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas.Oncoimmunology2021;10:1969767

[21] Sathe A,Lau BT.Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment.Clin Cancer Res2020;26:2640-53

[22] Biswas SK.Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.Nat Immunol2010;11:889-96

[23] Zhou J,Guo C.Crosstalk between macrophages and natural killer cells in the tumor microenvironment.Int Immunopharmacol2021;101:108374

[24] Zhang X.Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway.Gut2017;66:1878-80

[25] Iversen DB,Dalgård Dunvald AC,Stage TB.Drug metabolism and drug transport of the 100 most prescribed oral drugs.Basic Clin Pharmacol Toxicol2022;131:311-24 PMCID:PMC9804310

[26] Liu YN,Wang J.Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.Arch Toxicol2023;97:2133-42

[27] Hulshof EC,Nijenhuis M.Correction: dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Eur J Hum Genet2023;31:1088-9 PMCID:PMC10474007

[28] Haerian BS,Raymond AA.ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis.SeizureSeizure;19:339-46

[29] Liu H,Karsidag M,Wang P.Technical and biological biases in bulk transcriptomic data mining for cancer research.J Cancer2025;16:34-43 PMCID:PMC11660120

[30] Liu H,Wang P.Genetic expression in cancer research: challenges and complexity.Gene Rep24;37:102042

[31] Wang TT,Peng LS.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.Gut2017;66:1900-11 PMCID:PMC5739867

[32] Krami AM,Charoute H.Association between G2677T/A polymorphism in ABCB1 gene and the risk of drug resistance epilepsy: an updated systematic review and meta-analysis.Epilepsy Res2022;185:106977